Addition of bortezomib statistically enhanced the PFS and OS in previously untreated MM
Dr. Brian Durie discussed the randomized phase 3 SWOGG S0777 trial that investigated the addition of bortezomib to lenalidomide and dexamethasone for previously untreated multiple myeloma patients without an intend for immediate autologous stem cell transplant.
Source: International Myeloma Foundation - Category: Hematology Source Type: news
More News: Dexamethasone | Hematology | Myeloma | Revlimid | Statistics | Stem Cell Therapy | Stem Cells | Transplants | Velcade